AI Tokens
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data

Microsoft Excel

Two-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Sep 30, 2026 19.02% = 12.15% × 1.57
Jun 30, 2026 21.76% = 16.06% × 1.35
Mar 31, 2026 22.41% = 16.38% × 1.37
Dec 31, 2025 21.18% = 15.42% × 1.37
Sep 30, 2025 21.22% = 14.78% × 1.44
Jun 30, 2025 21.18% = 15.13% × 1.40
Mar 31, 2025 -5.99% = -4.32% × 1.39
Dec 31, 2024 -3.26% = -2.38% × 1.37
Sep 30, 2024 -3.07% = -2.16% × 1.42
Jun 30, 2024 -3.32% = -2.43% × 1.36
Mar 31, 2024 21.67% = 16.81% × 1.29
Dec 31, 2023 20.59% = 15.92% × 1.29
Sep 30, 2023 21.01% = 15.97% × 1.32
Jun 30, 2023 21.75% = 16.54% × 1.32
Mar 31, 2023 22.59% = 17.18% × 1.31
Dec 31, 2022 23.88% = 18.30% × 1.30
Sep 30, 2022 25.12% = 19.59% × 1.28
Jun 30, 2022 26.77% = 20.50% × 1.31
Mar 31, 2022 22.47% = 17.19% × 1.31

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance across the analyzed period is characterized by a strong baseline of profitability interrupted by a significant negative swing between June 2024 and March 2025. The overall return profile is primarily driven by operational efficiency rather than financial engineering, as the leverage ratio remains relatively stable throughout the timeline.

Return on Assets (ROA)
ROA maintained a consistent range between 15.92% and 20.50% from March 2022 through March 2024. A sharp reversal occurred in the second quarter of 2024, with values dropping into negative territory, reaching a low of -4.32% by March 2025. A recovery followed in June 2025, with ROA returning to a range of 14.78% to 16.38% through March 2026, before settling at 12.15% in September 2026.
Financial Leverage
The leverage ratio remained highly stable for the majority of the period, fluctuating narrowly between 1.28 and 1.32 from March 2022 to December 2023. A gradual upward trend emerged starting in 2024, with the ratio increasing to 1.44 by September 2025. A notable peak is observed in the final period of September 2026, where the ratio reached 1.57, indicating a slight increase in the use of debt to finance assets.
Return on Equity (ROE)
ROE closely mirrored the movements of ROA, reflecting the minimal impact of leverage on the overall return. Strong returns between 20.59% and 26.77% were observed from early 2022 to early 2024. The period of operational decline between June 2024 and March 2025 resulted in negative ROE, bottoming at -5.99%. Subsequent recovery saw ROE return to levels between 21.18% and 22.41% through March 2026, ending the period at 19.02% in September 2026.

The two-component disaggregation reveals that the volatility in ROE was almost exclusively a product of fluctuations in ROA. While financial leverage increased toward the end of the period, it was not sufficient to offset the decline in ROA seen in the final quarter, resulting in a moderate compression of ROE in September 2026.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Three-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Sep 30, 2026 19.02% = 30.70% × 0.40 × 1.57
Jun 30, 2026 21.76% = 35.00% × 0.46 × 1.35
Mar 31, 2026 22.41% = 35.51% × 0.46 × 1.37
Dec 31, 2025 21.18% = 32.94% × 0.47 × 1.37
Sep 30, 2025 21.22% = 31.35% × 0.47 × 1.44
Jun 30, 2025 21.18% = 31.86% × 0.48 × 1.40
Mar 31, 2025 -5.99% = -8.91% × 0.49 × 1.39
Dec 31, 2024 -3.26% = -4.86% × 0.49 × 1.37
Sep 30, 2024 -3.07% = -4.52% × 0.48 × 1.42
Jun 30, 2024 -3.32% = -4.74% × 0.51 × 1.36
Mar 31, 2024 21.67% = 39.46% × 0.43 × 1.29
Dec 31, 2023 20.59% = 36.68% × 0.43 × 1.29
Sep 30, 2023 21.01% = 35.94% × 0.44 × 1.32
Jun 30, 2023 21.75% = 35.40% × 0.47 × 1.32
Mar 31, 2023 22.59% = 35.40% × 0.49 × 1.31
Dec 31, 2022 23.88% = 37.20% × 0.49 × 1.30
Sep 30, 2022 25.12% = 37.62% × 0.52 × 1.28
Jun 30, 2022 26.77% = 38.26% × 0.54 × 1.31
Mar 31, 2022 22.47% = 30.84% × 0.56 × 1.31

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The Return on Equity (ROE) demonstrates a cyclical pattern characterized by a period of stability, a sharp contraction, and a subsequent recovery. The primary driver of these fluctuations is the net profit margin, while asset turnover and financial leverage exhibit more gradual and linear trends.

Net Profit Margin
Profitability remained robust between March 2022 and March 2024, peaking at 39.46%. However, a significant reversal occurred from June 2024 to March 2025, during which margins dropped into negative territory, reaching a low of -8.91% in March 2025. A recovery is observed starting in June 2025, with margins returning to the 30% to 35% range through September 2026.
Asset Turnover
A gradual downward trend in asset efficiency is evident, moving from a ratio of 0.56 in March 2022 to 0.40 by September 2026. Despite a brief spike to 0.51 in June 2024, the overall trajectory suggests a diminishing ability to generate revenue per unit of asset, indicating a long-term decline in operational efficiency.
Financial Leverage
The financial leverage ratio remained largely stagnant around 1.30 for the first two years. Beginning in June 2024, a steady increase is observed, peaking at 1.57 in September 2026. This indicates an increasing reliance on debt or a reduction in equity relative to total assets to bolster the return on equity.
Return on Equity (ROE) Synthesis
The ROE is highly sensitive to the net profit margin. The stable ROE range of 20% to 26% seen in 2022 and 2023 collapsed during the negative margin phase of 2024-2025, hitting a trough of -5.99% in March 2025. The eventual recovery of ROE to approximately 19% to 22% in 2026 is supported by the restoration of profit margins and a simultaneous increase in financial leverage, which partially offsets the consistent decline in asset turnover.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Five-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Sep 30, 2026 19.02% = 0.84 × 0.99 × 37.05% × 0.40 × 1.57
Jun 30, 2026 21.76% = 0.84 × 1.00 × 41.96% × 0.46 × 1.35
Mar 31, 2026 22.41% = 0.84 × 1.00 × 42.36% × 0.46 × 1.37
Dec 31, 2025 21.18% = 0.85 × 1.00 × 38.80% × 0.47 × 1.37
Sep 30, 2025 21.22% = 0.83 × 1.00 × 38.06% × 0.47 × 1.44
Jun 30, 2025 21.18% = 0.83 × 1.00 × 38.45% × 0.48 × 1.40
Mar 31, 2025 -5.99% = — × — × -2.50% × 0.49 × 1.39
Dec 31, 2024 -3.26% = -2.16 × 0.89 × 2.53% × 0.49 × 1.37
Sep 30, 2024 -3.07% = -1.85 × 0.87 × 2.80% × 0.48 × 1.42
Jun 30, 2024 -3.32% = -2.28 × 0.84 × 2.48% × 0.51 × 1.36
Mar 31, 2024 21.67% = 0.84 × 0.99 × 47.23% × 0.43 × 1.29
Dec 31, 2023 20.59% = 0.83 × 0.99 × 44.83% × 0.43 × 1.29
Sep 30, 2023 21.01% = 0.81 × 0.99 × 45.10% × 0.44 × 1.32
Jun 30, 2023 21.75% = 0.78 × 0.99 × 45.81% × 0.47 × 1.32
Mar 31, 2023 22.59% = 0.78 × 0.99 × 45.83% × 0.49 × 1.31
Dec 31, 2022 23.88% = 0.78 × 0.99 × 48.01% × 0.49 × 1.30
Sep 30, 2022 25.12% = 0.81 × 0.99 × 46.95% × 0.52 × 1.28
Jun 30, 2022 26.77% = 0.81 × 0.99 × 47.81% × 0.54 × 1.31
Mar 31, 2022 22.47% = 0.86 × 0.98 × 36.80% × 0.56 × 1.31

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


Return on Equity (ROE) exhibited a period of relative stability between 20.59% and 26.77% from early 2022 through early 2024. A significant contraction occurred mid-2024, with ROE descending into negative territory and reaching a trough of -5.99% in March 2025. A recovery followed, with values returning to the 19% to 22% range through September 2026.

Operational Profitability and Efficiency
The EBIT Margin was the primary driver of ROE volatility. While margins remained robust between 36.80% and 48.01% for the initial period, a severe collapse is observed between June 2024 and March 2025, where margins fell as low as -2.50%. Profitability recovered to levels between 37.05% and 42.36% by June 2025. Simultaneously, Asset Turnover demonstrated a consistent long-term decline, decreasing from 0.56 in March 2022 to 0.40 by September 2026, indicating a diminishing capacity to generate revenue from the asset base.
Tax and Interest Burdens
The Interest Burden remained consistently high, near 0.99, for the majority of the analysis period, suggesting that interest expenses had a negligible impact on operating profits. A temporary decline was noted in mid-2024, coinciding with the drop in EBIT. The Tax Burden showed stability around 0.78 to 0.86 for most quarters, though it experienced extreme volatility between June and December 2024, recording negative ratios that contributed to the overall instability of net income during that window.
Financial Leverage
Financial leverage remained relatively stable for the first several quarters, fluctuating between 1.28 and 1.32. A gradual upward trend emerged starting in June 2024, with the ratio increasing to 1.44 by September 2025 and peaking at 1.57 in September 2026. This indicates an increasing reliance on debt relative to equity to finance assets over the observed timeline.

The overall analysis indicates that while the company maintains strong operational margins and low interest sensitivity, a significant idiosyncratic event in 2024 severely impacted both EBIT and tax efficiency. The subsequent recovery in ROE was supported by a restoration of margins and an increase in financial leverage, despite a continuing decline in asset utilization efficiency.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Two-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Sep 30, 2026 12.15% = 30.70% × 0.40
Jun 30, 2026 16.06% = 35.00% × 0.46
Mar 31, 2026 16.38% = 35.51% × 0.46
Dec 31, 2025 15.42% = 32.94% × 0.47
Sep 30, 2025 14.78% = 31.35% × 0.47
Jun 30, 2025 15.13% = 31.86% × 0.48
Mar 31, 2025 -4.32% = -8.91% × 0.49
Dec 31, 2024 -2.38% = -4.86% × 0.49
Sep 30, 2024 -2.16% = -4.52% × 0.48
Jun 30, 2024 -2.43% = -4.74% × 0.51
Mar 31, 2024 16.81% = 39.46% × 0.43
Dec 31, 2023 15.92% = 36.68% × 0.43
Sep 30, 2023 15.97% = 35.94% × 0.44
Jun 30, 2023 16.54% = 35.40% × 0.47
Mar 31, 2023 17.18% = 35.40% × 0.49
Dec 31, 2022 18.30% = 37.20% × 0.49
Sep 30, 2022 19.59% = 37.62% × 0.52
Jun 30, 2022 20.50% = 38.26% × 0.54
Mar 31, 2022 17.19% = 30.84% × 0.56

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The Return on Assets (ROA) for the analyzed period exhibits significant volatility, driven primarily by fluctuations in net profit margins rather than changes in asset utilization efficiency. While the overall trend for ROA shows a decline from 17.19% in March 2022 to 12.15% in September 2026, the most notable feature is a period of negative returns occurring between June 2024 and March 2025.

Net Profit Margin
The net profit margin remained robust and relatively stable between 30.84% and 39.46% from March 2022 through March 2024. However, a sharp reversal occurred starting in June 2024, with margins turning negative and reaching a low of -8.91% by March 2025. A full recovery followed in June 2025, with margins returning to a range of 30.70% to 35.51% through the end of the period. This suggests a temporary but severe impact on profitability during the 2024-2025 fiscal window.
Asset Turnover
A consistent downward trend is observed in asset turnover, which declined from 0.56 in March 2022 to 0.40 by September 2026. Unlike the profit margin, this metric did not experience a sharp recovery, indicating a steady decrease in the efficiency with which assets are being utilized to generate revenue over the long term.
Return on Assets (ROA) Synthesis
The ROA movements closely mirror the trajectory of the net profit margin. The peak ROA of 20.50% in June 2022 was supported by both high margins and higher asset turnover. The subsequent dip into negative ROA values, reaching -4.32% in March 2025, was entirely attributable to the collapse in net profit margins, as asset turnover remained relatively stable during that specific interval. The final ROA of 12.15% reflects a compounded negative effect: while profitability recovered, the permanent erosion of asset turnover efficiency has prevented ROA from returning to its 2022 levels.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Four-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Sep 30, 2026 12.15% = 0.84 × 0.99 × 37.05% × 0.40
Jun 30, 2026 16.06% = 0.84 × 1.00 × 41.96% × 0.46
Mar 31, 2026 16.38% = 0.84 × 1.00 × 42.36% × 0.46
Dec 31, 2025 15.42% = 0.85 × 1.00 × 38.80% × 0.47
Sep 30, 2025 14.78% = 0.83 × 1.00 × 38.06% × 0.47
Jun 30, 2025 15.13% = 0.83 × 1.00 × 38.45% × 0.48
Mar 31, 2025 -4.32% = — × — × -2.50% × 0.49
Dec 31, 2024 -2.38% = -2.16 × 0.89 × 2.53% × 0.49
Sep 30, 2024 -2.16% = -1.85 × 0.87 × 2.80% × 0.48
Jun 30, 2024 -2.43% = -2.28 × 0.84 × 2.48% × 0.51
Mar 31, 2024 16.81% = 0.84 × 0.99 × 47.23% × 0.43
Dec 31, 2023 15.92% = 0.83 × 0.99 × 44.83% × 0.43
Sep 30, 2023 15.97% = 0.81 × 0.99 × 45.10% × 0.44
Jun 30, 2023 16.54% = 0.78 × 0.99 × 45.81% × 0.47
Mar 31, 2023 17.18% = 0.78 × 0.99 × 45.83% × 0.49
Dec 31, 2022 18.30% = 0.78 × 0.99 × 48.01% × 0.49
Sep 30, 2022 19.59% = 0.81 × 0.99 × 46.95% × 0.52
Jun 30, 2022 20.50% = 0.81 × 0.99 × 47.81% × 0.54
Mar 31, 2022 17.19% = 0.86 × 0.98 × 36.80% × 0.56

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analysis of the Return on Assets (ROA) reveals a period of relative stability followed by a significant volatility event in 2024 and a subsequent recovery phase. ROA generally fluctuated between 15.92% and 20.50% from early 2022 through early 2024, before experiencing a sharp decline into negative territory, reaching a trough of -4.32% by March 31, 2025. By June 30, 2025, the ROA recovered to 15.13%, though it showed a slight downward trajectory toward 12.15% by September 30, 2026.

EBIT Margin
The EBIT margin served as the primary driver of overall profitability and volatility. From March 2022 to March 2024, margins remained robust, peaking at 48.01% in December 2022. However, a severe contraction occurred between June 30, 2024, and March 31, 2025, where the margin collapsed from 47.23% to a low of -2.50%. A recovery followed, with margins returning to a range of 37.05% to 42.36% throughout 2025 and 2026, though these levels remained slightly below the 2022 peaks.
Asset Turnover
A consistent long-term downward trend is observed in asset turnover. Starting at 0.56 in March 2022, the ratio steadily declined to 0.40 by September 30, 2026. This gradual erosion suggests a decreasing efficiency in utilizing the asset base to generate revenue over the observed period, contributing to the long-term pressure on ROA regardless of margin fluctuations.
Tax Burden
The tax burden remained relatively stable, ranging between 0.78 and 0.86 for most of the period. A significant anomaly occurred between June 30, 2024, and December 31, 2024, during which the ratio turned sharply negative, reaching -2.28. This indicates substantial tax credits or one-time tax adjustments during the same window as the EBIT margin collapse. The ratio normalized to approximately 0.83 to 0.85 starting in June 2025.
Interest Burden
The interest burden remained the most stable component of the four-part analysis. For the majority of the timeframe, the ratio stayed near 0.99, indicating that interest expenses had a negligible impact on operating profits. A brief dip was observed in mid-2024, with values falling to 0.84, coinciding with the broader period of financial volatility, before returning to 1.00 in 2025.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Disaggregation of Net Profit Margin

Vertex Pharmaceuticals Inc., decomposition of net profit margin ratio (quarterly data)

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Sep 30, 2026 30.70% = 0.84 × 0.99 × 37.05%
Jun 30, 2026 35.00% = 0.84 × 1.00 × 41.96%
Mar 31, 2026 35.51% = 0.84 × 1.00 × 42.36%
Dec 31, 2025 32.94% = 0.85 × 1.00 × 38.80%
Sep 30, 2025 31.35% = 0.83 × 1.00 × 38.06%
Jun 30, 2025 31.86% = 0.83 × 1.00 × 38.45%
Mar 31, 2025 -8.91% = — × — × -2.50%
Dec 31, 2024 -4.86% = -2.16 × 0.89 × 2.53%
Sep 30, 2024 -4.52% = -1.85 × 0.87 × 2.80%
Jun 30, 2024 -4.74% = -2.28 × 0.84 × 2.48%
Mar 31, 2024 39.46% = 0.84 × 0.99 × 47.23%
Dec 31, 2023 36.68% = 0.83 × 0.99 × 44.83%
Sep 30, 2023 35.94% = 0.81 × 0.99 × 45.10%
Jun 30, 2023 35.40% = 0.78 × 0.99 × 45.81%
Mar 31, 2023 35.40% = 0.78 × 0.99 × 45.83%
Dec 31, 2022 37.20% = 0.78 × 0.99 × 48.01%
Sep 30, 2022 37.62% = 0.81 × 0.99 × 46.95%
Jun 30, 2022 38.26% = 0.81 × 0.99 × 47.81%
Mar 31, 2022 30.84% = 0.86 × 0.98 × 36.80%

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance exhibits a distinct three-phase trajectory: a period of sustained high profitability from early 2022 through early 2024, a severe contraction occurring between June 2024 and March 2025, and a subsequent recovery phase extending through September 2026. The primary driver of these fluctuations is the operational profitability, as evidenced by the volatility in the EBIT margin.

EBIT Margin Analysis
Operating profitability remained robust from March 2022 to March 2024, peaking at 48.01% in December 2022 and maintaining a floor above 44% for most of that period. A dramatic collapse is observed starting in June 2024, where the margin dropped to 2.48%, eventually turning negative at -2.50% by March 2025. Recovery began in June 2025, with margins returning to a range between 37.05% and 42.36%.
Tax Burden Analysis
The tax burden ratio remained stable between 0.78 and 0.86 during the initial growth and recovery phases. However, a significant anomaly occurred between June 2024 and December 2024, where the ratio turned negative, reaching as low as -2.28. This suggests the recognition of tax credits or deferred tax assets during the period of operating losses. The ratio normalized to approximately 0.84 by June 2025.
Interest Burden Analysis
The interest burden remained near unity (0.98 to 1.00) for the majority of the analyzed period, indicating that interest expenses had a negligible impact on the transition from EBIT to pre-tax income. A slight dip occurred between June 2024 and December 2024, with values ranging from 0.84 to 0.89, coinciding with the period of operational decline.
Net Profit Margin Integration
The net profit margin closely mirrored the trends of the EBIT margin, fluctuating between 30.84% and 39.46% during the stable periods. The sharp contraction in operational efficiency led to negative net margins, peaking at -8.91% in March 2025. The subsequent recovery saw margins climb back to a range of 30.70% to 35.51%, confirming that the overall profitability is primarily sensitive to operating performance rather than financing or tax structures.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?